Overview

Blinatumomab and Pembrolizumab for Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia With High Marrow Lymphoblasts

Status:
Recruiting

Trial end date:
2023-08-01

Target enrollment:

Participant gender:

Summary

This is a Phase I/II study of blinatumomab in combination with pembrolizumab in adult patients with relapsed or refractory B-lineage ALL The primary objective of this study is to determine if the addition of pembrolizumab to blinatumomab improves the overall response rate (CR+ CRh) relative to blinatumomab alone in adult subjects with relapsed or refractory B-cell acute lymphoblastic leukemia with high bone marrow lymphoblast percentage (>50% lymphoblasts).

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Matthew Wieduwilt, M.D., Ph.D.

Collaborators:

Amgen
Merck Sharp & Dohme Corp.

Treatments:

Antibodies, Bispecific
Blinatumomab
Pembrolizumab